Sublicensing Revenue Payments Sample Clauses

Sublicensing Revenue Payments. In addition, until the expiration of the last Valid Claim included in the applicable sublicensing agreement, Dermira shall pay Licensor a royalty equal to a percentage of the Sublicensing Revenue received by Dermira from a Sublicensee, determined based on the date that the applicable sublicensing agreement is entered into by Dermira and the Sublicensee in accordance with the following schedule: Effective Date of Sublicensing Agreement Applicable Percentage Within [*] after Effective Date [*]% More than [*] after Effective Date [*]% In the event the Sublicensing Revenue is nonmonetary (including without limitation a cross-license), it shall be assigned a fair market value in good faith and the specified percentage of that fair market value shall be paid to Licensor.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Sublicensing Revenue Payments. Each Party shall pay to the other Party a percentage of, in the case of Pioneer its Sublicensing Revenues in the Pioneer Agriculture Field, and in the case of Caribou Bio its Sublicensing Revenues in the [***], as follows, within [***] days after the calendar quarter in which the respective Sublicensing Revenues are received from the Sublicensee: [***]
Sample 1Sample 2
Sublicensing Revenue Payments. In the event Kuur (or an Affiliate Sublicensee) grants any sublicenses its license to one or more of the Licensed Products under the Core Platform Patent Rights under this Agreement, Kuur (itself or through its Affiliate) agrees to pay to Baylor the following percentages of Sublicensing Revenue received by Kuur during the Sublicensing Revenue Period (each such share, the “Revenue Share”):
Sample 1
Sublicensing Revenue Payments. In the event LICENSEE sublicenses the Patent Rights under this Agreement, LICENSEE agrees to pay to BCM the following percentages of all Sublicensing Revenue received by LICENSEE.
Sample 1
Sublicensing Revenue Payments. In the event Cell Medica (or an Affiliate Sublicensee) grants any sublicenses its license to one or more of the Licensed Products under the Core Platform Patent Rights under this Agreement, Cell Medica (itself or through its Affiliate) agrees to pay to Baylor the following percentages of Sublicensing Revenue received by Cell Medica during the Sublicensing Revenue Period (each such share, the “Revenue Share”):
Sample 1
Sublicensing Revenue Payments. During the Term of this Agreement, Licensee will pay to Licensor: (i) […***…] percent ([…***…]%) of Sublicensing Revenue for any sublicense of rights to Develop, Manufacture, Promote and/or Commercialize a Licensed Product pursuant to a Sublicense Agreement that is executed by Licensee and its Sublicensee within […***…] ([…***…]) months following the Effective Date of this Agreement; and (ii) […***…] percent ([…***…]%) of Sublicensing Revenue for any such sublicense of rights to Develop and/or Commercialize a Licensed Product executed thereafter.
Sample 1

Related to Sublicensing Revenue Payments

  • Sublicense Revenue In the event Licensee or an Affiliate of Licensee sublicenses under Section 2.2, Licensee shall pay CareFusion **THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION.** of any Sublicense Revenues resulting from sublicense agreements executed by Licensee.

  • Royalty Payments (i) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

  • Sublicense Income Company shall pay Medical School {***} of all Sublicense Income. Such amounts shall be due and payable within sixty (60) days after Company receives the relevant payment from the Sublicensee.

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • Royalty Fees In further consideration of the distribution rights and related rights granted by Shengqu to the Licensees hereunder, the Licensees shall pay to Shengqu a royalty fee equal to 35% of revenues on a monthly basis.

  • Royalties 8.1 In consideration of the license herein granted, LICENSEE shall pay royalties to LICENSOR as follows:

  • Royalty Payment In partial consideration of the grant of rights to Schering by ICN under this Agreement, Schering shall pay ICN a royalty in the following amount:

  • Earned Royalties Subject to of Article 7 hereof, Licensee shall pay to Licensor for the rights granted hereunder a sum equal to one and [*****] of the Net Invoice Value of Trademarked Products Sold by Licensee (the "Royalties"). The Royalties shall be remitted in accordance with Section 7.4 of this Agreement. 6.2

  • Sales Milestone Payments Licensee shall notify MTI of any Calendar Year in which annual Net Sales of a Licensed Product in such Calendar Year in all countries in the Territory reach the following thresholds for the first time within [***] days after the end of such Calendar Year, and shall make the following sales milestone payments to MTI within [***] days after receiving an invoice from MTI therefor: Annual Net Sales Threshold Sales Milestone Payment [***] [***] [***] [***] [***] [***] Each sales milestone payment is separate and may only be earned once for each Licensed Product, irrespective of the number of times such thresholds are achieved for such Licensed Product, but if more than one Net Sales threshold is reached in the same Calendar Year, all corresponding sales milestone payments shall be payable during such Calendar Year. For example, if annual Net Sales of a Licensed Product first reach [***] dollars [***] in Calendar Year 1, [***] dollars [***] shall be payable to MTI for such Calendar Year 1, however, if annual Net Sales of a Licensed Product first reach [***] dollars ($500,000,000) in Calendar Year 2 [***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. (without first reaching [***] dollars [***] in Calendar Year 1), then both the [***] dollars [***] and the [***] dollars [***] sales milestone payments would be payable to MTI for such Calendar Year 2. Net Sales of the Co-Exploited Product in the United States, which are subject to profit and loss sharing pursuant to the Co-Exploitation Terms, shall be excluded from the annual Net Sales of such Co-Exploited Product for purposes of this Section 7.10.

  • Royalty Rate Royalties shall be computed at the rate of six percent (6%) of Licensee's Net Sales during the applicable quarterly period.

Time is Money Join Law Insider Premium to draft better contracts faster.